Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization.

Saved in:
Bibliographic Details
Title: Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization.
Authors: Flynn CA; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., McAuley HJC; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Elneima O; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Aung HWW; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Ibrahim W; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Ward TJC; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Bourne M; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Thornton TD; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Mistry V; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Gilbert HR; Leicester Clinical Trials Unit, College of Life Sciences, University of Leicester, UK., Waheed G; Leicester Clinical Trials Unit, College of Life Sciences, University of Leicester, UK., Wright AKA; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Evans RA; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Steiner MC; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Brookes CL; Leicester Clinical Trials Unit, College of Life Sciences, University of Leicester, UK., Brightling CE; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK., Greening NJ; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, UK.
Source: NEJM evidence [NEJM Evid] 2025 Jun; Vol. 4 (6), pp. EVIDoa2500012. Date of Electronic Publication: 2025 Apr 30.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: NEJM Group, a division of the Massachusetts Medical Society Country of Publication: United States NLM ID: 9918317485806676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2766-5526 (Electronic) Linking ISSN: 27665526 NLM ISO Abbreviation: NEJM Evid Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2766-5526
DOI:10.1056/EVIDoa2500012